<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">17971464</PMID>
        <DateCompleted>
            <Year>2008</Year>
            <Month>04</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0306-6800</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>33</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of medical ethics</Title>
                <ISOAbbreviation>J Med Ethics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Uncomfortable implications: placebo equivalence in drug management of a functional illness.</ArticleTitle>
            <Pagination>
                <MedlinePgn>635-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Using a fictional but representative general practice consultation, involving the diagnosis of irritable bowel syndrome in a patient who is anxious for some relief from the discomfort his condition entails, this paper argues that when both (a) a drug fails to out-perform placebo and (b) the condition in question is a functional illness with no demonstrable underlying pathology, then the action of the drug is not only no better than placebo, and it is also no different from it either. The paper also argues that, in the circumstances of the consultation described, it is striking that current governance deems it ethical for a practitioner to prescribe either a drug or a placebo, both of which appear to rely for their effectiveness on a measure of concealment on the part of the doctor, yet deems it unethical for a practitioner openly to prescribe a harmless and enjoyable substance which (in equivalent conditions of transparency and information) is likely to be no less effective than either drug or placebo and is also likely to be better-tolerated and cheaper than the drug.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Evans</LastName>
                    <ForeName>H M</ForeName>
                    <Initials>HM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre for Arts and Humanities in Health and Medicine, Durham University, School House, St Hild's Lane, Durham DH1 1SZ, UK. h.m.evans@durham.ac.uk</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hungin</LastName>
                    <ForeName>A P S</ForeName>
                    <Initials>AP</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Med Ethics</MedlineTA>
            <NlmUniqueID>7513619</NlmUniqueID>
            <ISSNLinking>0306-6800</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009465">Neuromuscular Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010276">Parasympatholytics</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>E</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D004992" MajorTopicYN="N">Ethics, Medical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009465" MajorTopicYN="N">Neuromuscular Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010276" MajorTopicYN="N">Parasympatholytics</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012017" MajorTopicYN="N">Referral and Consultation</DescriptorName>
                <QualifierName UI="Q000941" MajorTopicYN="N">ethics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013035" MajorTopicYN="N">Spasm</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>4</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17971464</ArticleId>
            <ArticleId IdType="pii">33/11/635</ArticleId>
            <ArticleId IdType="doi">10.1136/jme.2006.019703</ArticleId>
            <ArticleId IdType="pmc">PMC2598109</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Gut. 2000 Jan;46(1):78-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10601059</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Aliment Pharmacol Ther. 2001 Mar;15(3):355-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11207510</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Digestion. 2001;64(3):200-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11786669</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2006 Apr;130(5):1480-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16678561</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Clin Pharmacol. 2003 Oct;56(4):362-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12968980</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Aliment Pharmacol Ther. 2004 Dec;20(11-12):1253-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15606387</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2006 Apr;130(5):1377-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16678553</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2002 Aug 17;360(9332):555-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12241674</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
